September 2011. Volume 7. Number 3

Final height does not affect the health-related quality of life in women with Turner syndrome

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Taback SP, Van Vliet G. Health-related quality of life of young adults with Turner syndrome following a long-term randomized controlled trial of recombinant human growth hormone. BMC Pediatr. 2011;11:49.
Reviewers: González Rodríguez MP1, Velarde Mayol C2.
1CS Barrio del Pilar. Área 5. Madrid. España.
2CS de Segovia 1. Segovia. España.
Correspondence: María Paz González Rodríguez. Email: pazgonz@gmail.com
Reception date: 24/08/2011
Acceptance date: 26/08/2011
Publication date: 07/09/2011

Abstract

Authors' conclusions: we found no benefit or adverse effect on health related quality of life in young adult women with Turner syndrome either from receiving or not receiving growth hormone injections. The results of this study in young adult women with Turner syndrome suggest that they adjust well to their challenges in life.

Reviewers' commentary: many girls with Turner syndrome receive growth hormone to improve their final height. Although this trial has some limitations, the perception of quality of life is not associated with their height. We must take into account other aspects of their life that could require support and treatment.

How to cite this article

González Rodríguez MP, Velarde Mayol C. La talla final no afecta a la calidad de vida de las mujeres con síndrome de Turner. Evid Pediatr. 2011;7:54.

AVC | Critically appraised articles

Taback SP, Van Vliet G. Health-related quality of life of young adults with Turner syndrome following a long-term randomized controlled trial of recombinant human growth hormone. BMC Pediatr. 2011;11:49.
Reviewers: González Rodríguez MP1, Velarde Mayol C2.
1CS Barrio del Pilar. Área 5. Madrid. España.
2CS de Segovia 1. Segovia. España.
Correspondence: María Paz González Rodríguez. Email: pazgonz@gmail.com
Reception date: 24/08/2011
Acceptance date: 26/08/2011
Publication date: 07/09/2011

How to cite this article

González Rodríguez MP, Velarde Mayol C. La talla final no afecta a la calidad de vida de las mujeres con síndrome de Turner. Evid Pediatr. 2011;7:54.

References

  1. Baxter L, Bryant J, Cave CB, Milne R. Hormona de crecimiento recombinante en niñas y adolescentes con síndrome de Turner (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.).
  2. Criterios para la utilización racional de la hormona de crecimiento en niños. Ministerio de Sanidad y Consumo. Dirección General de Farmacia y Productos Santarios. Comité asesor para la hormona de crecimiento. 30 mayo 2008 [en línea] [consultado: 14-VIII-2011]. Disponible en http://www.msps.es/profesionales/farmacia/pdf/criteriosHCninos020908.pdf
  3. Bannink EM, Raat H, Mulder PG, de Muinck Keizer-Schrama SM. Quality of life after growth hormone therapy and induced puberty in women with Turner syndrome. J Pediatr. 2006;148:95-101.
  4. Carel JC, Ecosse E, Bastie-Sigeac I, Cabrol S, Tauber M, Léger J et al. Quality of life determinants in young women with Turner´s syndrome after growth hormone treatment: results of the StaTur population-based cohort study. J Clin Endocrinol Metab. 2005;90:1992-7.
07/09/2011

Linked Comment